MAIA Biotechnology reduces ATM offering capacity from $30M to $11.2M

MAIA Biotechnology, Inc.

Maximum aggregate offering price reduced from $30M to $11.2M under ATM with H.C. Wainwright.
Prior sales: $6.29M in last 12 months, $11.63M total under the agreement.
Prospectus supplement dated March 26, 2025 filed for the $11.2M offering.
No reason given for reduction; company continues at-the-market program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.